SCHEMBL2303592

SCHEMBL2303592

COc1cc(NS(=O)(=O)c2ccc(N3CCNC3=O)cc2)cc(OC)c1OC

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
GHSR Q92847 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
HIF1A Q16665 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CYP1A1 P04798 3/20 0.44
LMNA P02545 2/20 0.44
PKM P14618 2/20 0.44
MAPK1 P28482 1/20 0.44
HTR6 P50406 3/20 0.43
GAA P10253 1/20 0.43
SCN9A Q15858 1/20 0.43
NPC1 O15118 1/20 0.43
FAM20C Q8IXL6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14217285 0.93 HTT (0.50) HTTSMN1; SMN2GHSRTP53MAPT
SCHEMBL2304631 0.89 LMNA (0.59) HTTSMN1; SMN2GHSRTP53MAPT
SCHEMBL2301551 0.86 HTR6 (0.53) HTTSMN1; SMN2MAPTHIF1ANPSR1
SCHEMBL2301155 0.82 KMT2A (0.61) HTTSMN1; SMN2MAPTLMNAPKM
SCHEMBL2301942 0.82 MAPT (0.54) HTTTP53MAPTLMNAPKM
SCHEMBL2302548 0.81 CYP1A1 (0.64) CYP1A1GAASCN9A
SCHEMBL2301616 0.81 LMNA (0.57) SMN1; SMN2TP53MAPTLMNAPKM
SCHEMBL2302868 0.81 ALDH1A1 (0.56) HTTSMN1; SMN2L3MBTL1HIF1ANPSR1
SCHEMBL2300282 0.79 ALDH1A1 (0.44) HTTSMN1; SMN2MAPTLMNAPKM
SCHEMBL2301965 0.78 ALDH1A1 (0.60) MAPTLMNAPKMMAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 HTT 4006/4885SMN1; SMN2 2479/4885GHSR 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.